Quanterix Corporation

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, ABT has a market cap of 237.1B. Regarding current trading prices, QTRX is priced at $6.65, while ABT trades at $136.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas ABT's P/E ratio is 17.72. In terms of profitability, QTRX's ROE is -0.15%, compared to ABT's ROE of +0.31%. Regarding short-term risk, QTRX is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, QTRX is priced at $6.65, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, QTRX's ROE is -0.15%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, QTRX is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, BSX has a market cap of 155B. Regarding current trading prices, QTRX is priced at $6.65, while BSX trades at $107.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas BSX's P/E ratio is 76.46. In terms of profitability, QTRX's ROE is -0.15%, compared to BSX's ROE of +0.10%. Regarding short-term risk, QTRX is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, SYK has a market cap of 151.6B. Regarding current trading prices, QTRX is priced at $6.65, while SYK trades at $395.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas SYK's P/E ratio is 53.68. In terms of profitability, QTRX's ROE is -0.15%, compared to SYK's ROE of +0.11%. Regarding short-term risk, QTRX is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, MDT has a market cap of 113.7B. Regarding current trading prices, QTRX is priced at $6.65, while MDT trades at $87.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas MDT's P/E ratio is 24.58. In terms of profitability, QTRX's ROE is -0.15%, compared to MDT's ROE of +0.10%. Regarding short-term risk, QTRX is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, EW has a market cap of 45.3B. Regarding current trading prices, QTRX is priced at $6.65, while EW trades at $78.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas EW's P/E ratio is 31.90. In terms of profitability, QTRX's ROE is -0.15%, compared to EW's ROE of +0.49%. Regarding short-term risk, QTRX is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, DXCM has a market cap of 32.8B. Regarding current trading prices, QTRX is priced at $6.65, while DXCM trades at $87.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas DXCM's P/E ratio is 62.84. In terms of profitability, QTRX's ROE is -0.15%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, QTRX is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, STE has a market cap of 23.9B. Regarding current trading prices, QTRX is priced at $6.65, while STE trades at $240.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas STE's P/E ratio is 39.39. In terms of profitability, QTRX's ROE is -0.15%, compared to STE's ROE of +0.09%. Regarding short-term risk, QTRX is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, PHG has a market cap of 22.4B. Regarding current trading prices, QTRX is priced at $6.65, while PHG trades at $23.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas PHG's P/E ratio is 80.65. In terms of profitability, QTRX's ROE is -0.15%, compared to PHG's ROE of +0.03%. Regarding short-term risk, QTRX is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, PODD has a market cap of 21.1B. Regarding current trading prices, QTRX is priced at $6.65, while PODD trades at $314.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas PODD's P/E ratio is 54.05. In terms of profitability, QTRX's ROE is -0.15%, compared to PODD's ROE of +0.35%. Regarding short-term risk, QTRX is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, ZBH has a market cap of 18.6B. Regarding current trading prices, QTRX is priced at $6.65, while ZBH trades at $91.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas ZBH's P/E ratio is 20.90. In terms of profitability, QTRX's ROE is -0.15%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, QTRX is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, QTRX is priced at $6.65, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas ABMD's P/E ratio is 65.36. In terms of profitability, QTRX's ROE is -0.15%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, QTRX is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, ALGN has a market cap of 14.1B. Regarding current trading prices, QTRX is priced at $6.65, while ALGN trades at $189.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas ALGN's P/E ratio is 35.26. In terms of profitability, QTRX's ROE is -0.15%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, QTRX is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, SNN has a market cap of 13.4B. Regarding current trading prices, QTRX is priced at $6.65, while SNN trades at $30.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas SNN's P/E ratio is 32.56. In terms of profitability, QTRX's ROE is -0.15%, compared to SNN's ROE of +0.08%. Regarding short-term risk, QTRX is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, QTRX is priced at $6.65, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas SWAV's P/E ratio is 78.76. In terms of profitability, QTRX's ROE is -0.15%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, QTRX is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, PEN has a market cap of 9.7B. Regarding current trading prices, QTRX is priced at $6.65, while PEN trades at $256.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas PEN's P/E ratio is 232.44. In terms of profitability, QTRX's ROE is -0.15%, compared to PEN's ROE of +0.04%. Regarding short-term risk, QTRX is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, GMED has a market cap of 8.1B. Regarding current trading prices, QTRX is priced at $6.65, while GMED trades at $59.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas GMED's P/E ratio is 44.90. In terms of profitability, QTRX's ROE is -0.15%, compared to GMED's ROE of +0.05%. Regarding short-term risk, QTRX is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, BIO-B has a market cap of 6.8B. Regarding current trading prices, QTRX is priced at $6.65, while BIO-B trades at $250.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, QTRX's ROE is -0.15%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, QTRX is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, BIO has a market cap of 6.7B. Regarding current trading prices, QTRX is priced at $6.65, while BIO trades at $241.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas BIO's P/E ratio is -3.24. In terms of profitability, QTRX's ROE is -0.15%, compared to BIO's ROE of -0.32%. Regarding short-term risk, QTRX is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, BRKR has a market cap of 6.3B. Regarding current trading prices, QTRX is priced at $6.65, while BRKR trades at $41.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas BRKR's P/E ratio is 80.58. In terms of profitability, QTRX's ROE is -0.15%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, QTRX is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, GKOS has a market cap of 5.9B. Regarding current trading prices, QTRX is priced at $6.65, while GKOS trades at $103.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas GKOS's P/E ratio is -45.20. In terms of profitability, QTRX's ROE is -0.15%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, QTRX is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, QTRX is priced at $6.65, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas NARI's P/E ratio is -59.24. In terms of profitability, QTRX's ROE is -0.15%, compared to NARI's ROE of -0.18%. Regarding short-term risk, QTRX is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, IRTC has a market cap of 4.7B. Regarding current trading prices, QTRX is priced at $6.65, while IRTC trades at $153.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas IRTC's P/E ratio is -46.78. In terms of profitability, QTRX's ROE is -0.15%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, QTRX is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, TMDX has a market cap of 4.4B. Regarding current trading prices, QTRX is priced at $6.65, while TMDX trades at $134.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas TMDX's P/E ratio is 91.62. In terms of profitability, QTRX's ROE is -0.15%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, QTRX is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, QTRX is priced at $6.65, while ITGR trades at $122.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas ITGR's P/E ratio is 56.70. In terms of profitability, QTRX's ROE is -0.15%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, QTRX is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, INSP has a market cap of 3.9B. Regarding current trading prices, QTRX is priced at $6.65, while INSP trades at $129.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas INSP's P/E ratio is 59.76. In terms of profitability, QTRX's ROE is -0.15%, compared to INSP's ROE of +0.10%. Regarding short-term risk, QTRX is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, QTRX is priced at $6.65, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas AXNX's P/E ratio is -709.80. In terms of profitability, QTRX's ROE is -0.15%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, QTRX is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, PRCT has a market cap of 3.1B. Regarding current trading prices, QTRX is priced at $6.65, while PRCT trades at $57.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas PRCT's P/E ratio is -33.47. In terms of profitability, QTRX's ROE is -0.15%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, QTRX is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, LIVN has a market cap of 2.5B. Regarding current trading prices, QTRX is priced at $6.65, while LIVN trades at $45.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas LIVN's P/E ratio is -11.24. In terms of profitability, QTRX's ROE is -0.15%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, QTRX is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, QTRX is priced at $6.65, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas NUVA's P/E ratio is 75.00. In terms of profitability, QTRX's ROE is -0.15%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, QTRX is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, UFPT has a market cap of 1.9B. Regarding current trading prices, QTRX is priced at $6.65, while UFPT trades at $244.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas UFPT's P/E ratio is 30.96. In terms of profitability, QTRX's ROE is -0.15%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, QTRX is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, CNMD has a market cap of 1.7B. Regarding current trading prices, QTRX is priced at $6.65, while CNMD trades at $52.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas CNMD's P/E ratio is 14.19. In terms of profitability, QTRX's ROE is -0.15%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, QTRX is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, QTRX is priced at $6.65, while ATEC trades at $11.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas ATEC's P/E ratio is -9.59. In terms of profitability, QTRX's ROE is -0.15%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, QTRX is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, QTRX is priced at $6.65, while AORT trades at $31.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas AORT's P/E ratio is -60.26. In terms of profitability, QTRX's ROE is -0.15%, compared to AORT's ROE of -0.07%. Regarding short-term risk, QTRX is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, QTRX is priced at $6.65, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas HSKA's P/E ratio is -62.49. In terms of profitability, QTRX's ROE is -0.15%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, QTRX is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, QTRX is priced at $6.65, while AHCO trades at $9.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas AHCO's P/E ratio is 16.21. In terms of profitability, QTRX's ROE is -0.15%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, QTRX is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, ESTA has a market cap of 1.3B. Regarding current trading prices, QTRX is priced at $6.65, while ESTA trades at $42.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas ESTA's P/E ratio is -13.91. In terms of profitability, QTRX's ROE is -0.15%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, QTRX is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, QTRX is priced at $6.65, while TNDM trades at $18.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas TNDM's P/E ratio is -6.18. In terms of profitability, QTRX's ROE is -0.15%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, QTRX is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, QTRX is priced at $6.65, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas SILK's P/E ratio is -18.96. In terms of profitability, QTRX's ROE is -0.15%, compared to SILK's ROE of -0.29%. Regarding short-term risk, QTRX is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, QTRX is priced at $6.65, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas FNA's P/E ratio is -19.83. In terms of profitability, QTRX's ROE is -0.15%, compared to FNA's ROE of -0.36%. Regarding short-term risk, QTRX is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, SSII has a market cap of 1.1B. Regarding current trading prices, QTRX is priced at $6.65, while SSII trades at $5.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas SSII's P/E ratio is -70.75. In terms of profitability, QTRX's ROE is -0.15%, compared to SSII's ROE of -1.33%. Regarding short-term risk, QTRX is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, INMD has a market cap of 1B. Regarding current trading prices, QTRX is priced at $6.65, while INMD trades at $14.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas INMD's P/E ratio is 6.65. In terms of profitability, QTRX's ROE is -0.15%, compared to INMD's ROE of +0.25%. Regarding short-term risk, QTRX is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, IART has a market cap of 1B. Regarding current trading prices, QTRX is priced at $6.65, while IART trades at $12.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas IART's P/E ratio is -34.87. In terms of profitability, QTRX's ROE is -0.15%, compared to IART's ROE of -0.03%. Regarding short-term risk, QTRX is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, QTRX is priced at $6.65, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas CSII's P/E ratio is -20.83. In terms of profitability, QTRX's ROE is -0.15%, compared to CSII's ROE of -0.14%. Regarding short-term risk, QTRX is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, SIBN has a market cap of 780.3M. Regarding current trading prices, QTRX is priced at $6.65, while SIBN trades at $18.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas SIBN's P/E ratio is -29.06. In terms of profitability, QTRX's ROE is -0.15%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, QTRX is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, IRMD has a market cap of 769.4M. Regarding current trading prices, QTRX is priced at $6.65, while IRMD trades at $59.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas IRMD's P/E ratio is 39.04. In terms of profitability, QTRX's ROE is -0.15%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, QTRX is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, QTRX is priced at $6.65, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas CRY's P/E ratio is 425.71. In terms of profitability, QTRX's ROE is -0.15%, compared to CRY's ROE of -0.07%. Regarding short-term risk, QTRX is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, CBLL has a market cap of 671.2M. Regarding current trading prices, QTRX is priced at $6.65, while CBLL trades at $18.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas CBLL's P/E ratio is -14.86. In terms of profitability, QTRX's ROE is -0.15%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, QTRX is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, BFLY-WT has a market cap of 584.9M. Regarding current trading prices, QTRX is priced at $6.65, while BFLY-WT trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, QTRX's ROE is -0.15%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, QTRX is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, QTRX is priced at $6.65, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas APEN's P/E ratio is -9.43. In terms of profitability, QTRX's ROE is -0.15%, compared to APEN's ROE of -0.85%. Regarding short-term risk, QTRX is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, AVNS has a market cap of 577.6M. Regarding current trading prices, QTRX is priced at $6.65, while AVNS trades at $12.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas AVNS's P/E ratio is -1.51. In terms of profitability, QTRX's ROE is -0.15%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, QTRX is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, KIDS has a market cap of 541.5M. Regarding current trading prices, QTRX is priced at $6.65, while KIDS trades at $21.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas KIDS's P/E ratio is -12.42. In terms of profitability, QTRX's ROE is -0.15%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, QTRX is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, RXST has a market cap of 533.2M. Regarding current trading prices, QTRX is priced at $6.65, while RXST trades at $13.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas RXST's P/E ratio is -19.88. In terms of profitability, QTRX's ROE is -0.15%, compared to RXST's ROE of -0.10%. Regarding short-term risk, QTRX is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, AXGN has a market cap of 499.2M. Regarding current trading prices, QTRX is priced at $6.65, while AXGN trades at $10.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas AXGN's P/E ratio is -68.50. In terms of profitability, QTRX's ROE is -0.15%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, QTRX is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, BFLY has a market cap of 478.5M. Regarding current trading prices, QTRX is priced at $6.65, while BFLY trades at $2.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas BFLY's P/E ratio is -6.45. In terms of profitability, QTRX's ROE is -0.15%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, QTRX is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, BVS has a market cap of 462.5M. Regarding current trading prices, QTRX is priced at $6.65, while BVS trades at $6.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas BVS's P/E ratio is -14.52. In terms of profitability, QTRX's ROE is -0.15%, compared to BVS's ROE of -0.21%. Regarding short-term risk, QTRX is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, CTKB has a market cap of 440.8M. Regarding current trading prices, QTRX is priced at $6.65, while CTKB trades at $3.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas CTKB's P/E ratio is -38.67. In terms of profitability, QTRX's ROE is -0.15%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, QTRX is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, OFIX has a market cap of 438M. Regarding current trading prices, QTRX is priced at $6.65, while OFIX trades at $11.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas OFIX's P/E ratio is -3.02. In terms of profitability, QTRX's ROE is -0.15%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, QTRX is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, SRDX has a market cap of 418.7M. Regarding current trading prices, QTRX is priced at $6.65, while SRDX trades at $29.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas SRDX's P/E ratio is -20.91. In terms of profitability, QTRX's ROE is -0.15%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, QTRX is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, SMLR has a market cap of 395M. Regarding current trading prices, QTRX is priced at $6.65, while SMLR trades at $38.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas SMLR's P/E ratio is -14.82. In terms of profitability, QTRX's ROE is -0.15%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, QTRX is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, PACB has a market cap of 387.1M. Regarding current trading prices, QTRX is priced at $6.65, while PACB trades at $1.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas PACB's P/E ratio is -0.47. In terms of profitability, QTRX's ROE is -0.15%, compared to PACB's ROE of -1.70%. Regarding short-term risk, QTRX is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, TMCI has a market cap of 378.7M. Regarding current trading prices, QTRX is priced at $6.65, while TMCI trades at $5.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas TMCI's P/E ratio is -7.08. In terms of profitability, QTRX's ROE is -0.15%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, QTRX is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, OM has a market cap of 367.4M. Regarding current trading prices, QTRX is priced at $6.65, while OM trades at $19.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas OM's P/E ratio is -0.72. In terms of profitability, QTRX's ROE is -0.15%, compared to OM's ROE of -1.45%. Regarding short-term risk, QTRX is more volatile compared to OM. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, SENS has a market cap of 361.5M. Regarding current trading prices, QTRX is priced at $6.65, while SENS trades at $0.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas SENS's P/E ratio is -4.36. In terms of profitability, QTRX's ROE is -0.15%, compared to SENS's ROE of -7.46%. Regarding short-term risk, QTRX is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, VREX has a market cap of 355.7M. Regarding current trading prices, QTRX is priced at $6.65, while VREX trades at $8.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas VREX's P/E ratio is -8.32. In terms of profitability, QTRX's ROE is -0.15%, compared to VREX's ROE of -0.08%. Regarding short-term risk, QTRX is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, NPCE has a market cap of 343.7M. Regarding current trading prices, QTRX is priced at $6.65, while NPCE trades at $11.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas NPCE's P/E ratio is -12.78. In terms of profitability, QTRX's ROE is -0.15%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, QTRX is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, NNOX has a market cap of 326.1M. Regarding current trading prices, QTRX is priced at $6.65, while NNOX trades at $5.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas NNOX's P/E ratio is -5.62. In terms of profitability, QTRX's ROE is -0.15%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, QTRX is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, CLPT has a market cap of 318.3M. Regarding current trading prices, QTRX is priced at $6.65, while CLPT trades at $11.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas CLPT's P/E ratio is -14.82. In terms of profitability, QTRX's ROE is -0.15%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, QTRX is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, CERS has a market cap of 282.9M. Regarding current trading prices, QTRX is priced at $6.65, while CERS trades at $1.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas CERS's P/E ratio is -14.80. In terms of profitability, QTRX's ROE is -0.15%, compared to CERS's ROE of -0.35%. Regarding short-term risk, QTRX is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, VMD has a market cap of 276.7M. Regarding current trading prices, QTRX is priced at $6.65, while VMD trades at $6.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas VMD's P/E ratio is 23.33. In terms of profitability, QTRX's ROE is -0.15%, compared to VMD's ROE of +0.10%. Regarding short-term risk, QTRX is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, SNWV has a market cap of 275.7M. Regarding current trading prices, QTRX is priced at $6.65, while SNWV trades at $32.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas SNWV's P/E ratio is -5.17. In terms of profitability, QTRX's ROE is -0.15%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, QTRX is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, ZIMV has a market cap of 274.7M. Regarding current trading prices, QTRX is priced at $6.65, while ZIMV trades at $9.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas ZIMV's P/E ratio is -10.93. In terms of profitability, QTRX's ROE is -0.15%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, QTRX is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, PTHL has a market cap of 261.2M. Regarding current trading prices, QTRX is priced at $6.65, while PTHL trades at $18.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas PTHL's P/E ratio is -366.60. In terms of profitability, QTRX's ROE is -0.15%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, QTRX is more volatile compared to PTHL. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, BWAY has a market cap of 245.2M. Regarding current trading prices, QTRX is priced at $6.65, while BWAY trades at $13.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas BWAY's P/E ratio is 58.98. In terms of profitability, QTRX's ROE is -0.15%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, QTRX is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, CATX has a market cap of 242.7M. Regarding current trading prices, QTRX is priced at $6.65, while CATX trades at $3.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas CATX's P/E ratio is -2.66. In terms of profitability, QTRX's ROE is -0.15%, compared to CATX's ROE of -0.27%. Regarding short-term risk, QTRX is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, TCMD has a market cap of 237.8M. Regarding current trading prices, QTRX is priced at $6.65, while TCMD trades at $10.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas TCMD's P/E ratio is 15.50. In terms of profitability, QTRX's ROE is -0.15%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, QTRX is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, MASS has a market cap of 232.4M. Regarding current trading prices, QTRX is priced at $6.65, while MASS trades at $7.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas MASS's P/E ratio is -2.92. In terms of profitability, QTRX's ROE is -0.15%, compared to MASS's ROE of -0.13%. Regarding short-term risk, QTRX is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, MXCT has a market cap of 230.7M. Regarding current trading prices, QTRX is priced at $6.65, while MXCT trades at $2.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas MXCT's P/E ratio is -5.42. In terms of profitability, QTRX's ROE is -0.15%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, QTRX is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, BSGM has a market cap of 227.1M. Regarding current trading prices, QTRX is priced at $6.65, while BSGM trades at $7.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas BSGM's P/E ratio is -15.70. In terms of profitability, QTRX's ROE is -0.15%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, QTRX is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, QTRX is priced at $6.65, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas NVRO's P/E ratio is -1.91. In terms of profitability, QTRX's ROE is -0.15%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, QTRX is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, SGHT has a market cap of 210.4M. Regarding current trading prices, QTRX is priced at $6.65, while SGHT trades at $4.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas SGHT's P/E ratio is -4.15. In terms of profitability, QTRX's ROE is -0.15%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, QTRX is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, QTRX is priced at $6.65, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas EYES's P/E ratio is N/A. In terms of profitability, QTRX's ROE is -0.15%, compared to EYES's ROE of -0.26%. Regarding short-term risk, QTRX is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, TLSI has a market cap of 195.6M. Regarding current trading prices, QTRX is priced at $6.65, while TLSI trades at $5.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas TLSI's P/E ratio is -4.68. In terms of profitability, QTRX's ROE is -0.15%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, QTRX is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, INGN has a market cap of 190.9M. Regarding current trading prices, QTRX is priced at $6.65, while INGN trades at $7.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas INGN's P/E ratio is -6.17. In terms of profitability, QTRX's ROE is -0.15%, compared to INGN's ROE of -0.15%. Regarding short-term risk, QTRX is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, PROF has a market cap of 183.4M. Regarding current trading prices, QTRX is priced at $6.65, while PROF trades at $5.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas PROF's P/E ratio is -5.04. In terms of profitability, QTRX's ROE is -0.15%, compared to PROF's ROE of -0.70%. Regarding short-term risk, QTRX is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, ELMD has a market cap of 181.5M. Regarding current trading prices, QTRX is priced at $6.65, while ELMD trades at $21.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas ELMD's P/E ratio is 27.39. In terms of profitability, QTRX's ROE is -0.15%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, QTRX is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, CVRX has a market cap of 157.5M. Regarding current trading prices, QTRX is priced at $6.65, while CVRX trades at $5.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas CVRX's P/E ratio is -2.82. In terms of profitability, QTRX's ROE is -0.15%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, QTRX is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, RPID has a market cap of 153M. Regarding current trading prices, QTRX is priced at $6.65, while RPID trades at $3.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas RPID's P/E ratio is -3.39. In terms of profitability, QTRX's ROE is -0.15%, compared to RPID's ROE of -0.56%. Regarding short-term risk, QTRX is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, LNSR has a market cap of 152.3M. Regarding current trading prices, QTRX is priced at $6.65, while LNSR trades at $13.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas LNSR's P/E ratio is -2.63. In terms of profitability, QTRX's ROE is -0.15%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, QTRX is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, ANIK has a market cap of 151M. Regarding current trading prices, QTRX is priced at $6.65, while ANIK trades at $10.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas ANIK's P/E ratio is -14.04. In terms of profitability, QTRX's ROE is -0.15%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, QTRX is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, RCEL has a market cap of 139.3M. Regarding current trading prices, QTRX is priced at $6.65, while RCEL trades at $5.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas RCEL's P/E ratio is -2.41. In terms of profitability, QTRX's ROE is -0.15%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, QTRX is more volatile compared to RCEL. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, AVR has a market cap of 138.7M. Regarding current trading prices, QTRX is priced at $6.65, while AVR trades at $3.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas AVR's P/E ratio is -1.07. In terms of profitability, QTRX's ROE is -0.15%, compared to AVR's ROE of -2.92%. Regarding short-term risk, QTRX is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, OWLT has a market cap of 138.5M. Regarding current trading prices, QTRX is priced at $6.65, while OWLT trades at $8.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas OWLT's P/E ratio is -5.20. In terms of profitability, QTRX's ROE is -0.15%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, QTRX is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, BDMD has a market cap of 137.9M. Regarding current trading prices, QTRX is priced at $6.65, while BDMD trades at $3.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas BDMD's P/E ratio is 7.88. In terms of profitability, QTRX's ROE is -0.15%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, QTRX is less volatile compared to BDMD. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, LUCD has a market cap of 119M. Regarding current trading prices, QTRX is priced at $6.65, while LUCD trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas LUCD's P/E ratio is -0.94. In terms of profitability, QTRX's ROE is -0.15%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, QTRX is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, LUNG has a market cap of 108.3M. Regarding current trading prices, QTRX is priced at $6.65, while LUNG trades at $2.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas LUNG's P/E ratio is -1.87. In terms of profitability, QTRX's ROE is -0.15%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, QTRX is more volatile compared to LUNG. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, ICAD has a market cap of 102.2M. Regarding current trading prices, QTRX is priced at $6.65, while ICAD trades at $3.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas ICAD's P/E ratio is -19.58. In terms of profitability, QTRX's ROE is -0.15%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, QTRX is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, MGRM has a market cap of 102.1M. Regarding current trading prices, QTRX is priced at $6.65, while MGRM trades at $2.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas MGRM's P/E ratio is -5.72. In terms of profitability, QTRX's ROE is -0.15%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, QTRX is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for QTRX.

QTRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QTRX stands at 259.9M. In comparison, XTNT has a market cap of 99.6M. Regarding current trading prices, QTRX is priced at $6.65, while XTNT trades at $0.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QTRX currently has a P/E ratio of -5.40, whereas XTNT's P/E ratio is -7.95. In terms of profitability, QTRX's ROE is -0.15%, compared to XTNT's ROE of -0.27%. Regarding short-term risk, QTRX is less volatile compared to XTNT. This indicates potentially lower risk in terms of short-term price fluctuations for QTRX.